On May 29, 2013 Alethia Biotherapeutics Inc., a privately held biotechnology company focused on developing therapeutic monoclonal antibodies (mAb) reported that it has entered into a global strategic alliance with the International Biotechnology Center (IBC) Generium to jointly develop AB-16B5, a mAB inhibitor of epithelial-to-mesenchymal transition (EMT) (Company Pipeline, Alethia Biotherapeutics, MAY 29, 2013, View Source [SID1234518222]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the alliance, Alethia and IBC Generium will collaborate for the ongoing development of AB-16B5 and, upon completion of the initial clinical study, share equally in the downstream economics in territories outside Russia and the CIS states. Alethia will receive an upfront cash payment and R&D funding to conduct the initial clinical study in Canada. In addition, to an exclusive license granted to IBC Generium for other territories, IBC Generium has also been granted the right to an exclusive license for Russia and the CIS states for which development milestones and royalties would be payable to Alethia. Further financial terms were not disclosed.

"We are very excited to conclude this global strategic alliance with IBC Generium," said Yves Cornellier, President and CEO of Alethia. "Like Alethia, IBC Generium is dedicated to improving the treatments available to cancer patients and is committing significant resources to develop innovative biological therapeutics including AB-16B5"

Mr. Daniil Talyanskiy, Chief Business Officer at IBC Generium commented: "We are very pleased to have formed this global strategic alliance with Alethia. EMT is a key contributor to both tumor invasion and the emergence of resistance to many cancer therapies. The excellent EMT inhibitor program developed at Alethia represents a unique opportunity for our company to accelerate the development of a novel therapy with potential applications in multiple cancer indications."

"This transaction with IBC Generium represents an important milestone for Alethia" commented Mrs. Ela Borenstein from BDC Capital. "It serves as recognition of the excellent preclinical development performed at Alethia to date, added Mr. Louis Lacasse of Agechem Venture Fund. Progressing to a clinical stage company through the advancement of AB-16B5 contributes to the potential for material value creation for Alethia’s shareholders."

On May 20, 2013 Ignyta, Inc. reported that it has acquired Actagene Oncology, Inc., effective May 20, 2013. Actagene was a San Diego based privately held biotechnology company founded in February 2013 that was developing personalized medicines for high unmet need cancer indications, based on cancer genome mining and sequencing (Press release, Ignyta, MAY 20, 2013, View Source [SID1234625377]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With the acquisition, Ignyta has evolved its business strategy from a sole focus on molecular diagnostics for autoimmune disease to an integrated "Rx/Dx" focus on drug and biomarker discovery and development for cancer and immunology. Patrick O’Connor, Ph.D., CEO of Actagene Oncology, has joined Ignyta as Chief Scientific Officer and SVP, Head of Research. His contributions to the field of oncology include over 100 publications and patents and over 20 compounds brought into development, including the recently approved anticancer drugs Xalkori (Crizotinib) and Inlyta (Axitinib), discovered at Pfizer where Dr. O’Connor served as the Global Research Therapeutic Area Head for Oncology.

Other additions to Ignyta’s management team include Jean-Michel Vernier, Ph.D., who formerly led chemistry groups at Ardea Biosciences, Valeant Pharmaceuticals and Merck Research Laboratories, to serve as VP, Medicinal Chemistry; Paul Pearson, Ph.D., former Global Head and VP, Pharmacokinetics and Drug Metabolism at Amgen, to head PK, Drug Metabolism & Safety; and Dave Matthews, Ph.D., the scientific founder of Agouron Pharmaceuticals, to head Crystallography at Ignyta. James Bristol, Ph.D., former Worldwide Head of Pfizer Discovery and Former Head of Discovery and Chemistry at Warner-Lambert/Parke Davis, at which site Lipitor was discovered by his Chemistry team, joined Ignyta’s Scientific Advisory Board.

"The Actagene acquisition provides Ignyta with a strategic entry into oncology personalized medicine, an area with high unmet medical need and opportunities to give patients customized treatment options that leverage Ignyta’s biomarker discovery capabilities. Ignyta also gains the addition of Patrick O’Connor and the rest of his world class oncology drug hunter team that has collectively discovered and developed 10 approved drugs representing over $5 billion in 2012 sales," said Jonathan Lim, M.D., chairman and CEO of Ignyta. "Actagene’s R&D team complements Ignyta’s existing team, platform and capabilities, such as whole genome methylation analysis, next generation sequencing, Methylome database, and bioinformatics expertise. This transaction reshapes us into a seamless Rx/Dx company pursuing a significant growth area of patient stratification and targeted drug discovery and development for cancer patients."

Actagene Oncology applies its proprietary Oncolome database and technologies such as synthetic lethal screening, x-ray crystallography and structure-based drug design to develop new chemical entities against genetic targets that are enriched in certain cancer populations.

"I am excited for the Actagene team to join forces with the Ignyta team, several of whom I had the pleasure to previously work with when I was at Halozyme," said Dr. O’Connor. "Actagene’s Oncolome platform will combine synergistically with Ignyta’s Methylome platform to provide both genetic and epigenetic insights from patient tumor samples to identify and pursue personalized medicines against activated genes in cancer. The driving scientific focus for our new company will be the discovery and development of revolutionary new drugs targeting activated genes driving cancer growth and evasion of the immune system."

In addition to its new focus on targeted therapeutic discovery for cancer, Ignyta will continue to advance its companion diagnostic initiatives to generate epigenetic signatures that are predictive of treatment response for specific drug mechanisms within both autoimmune disease and cancer.

(Filing, 10-Q, iBio, MAY 20, 2013, View Source [SID:1234502734])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Filing, 10-Q, TNI BioTech, MAY 15, 2013, View Source [SID:1234502812])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 13, 2013 Sorrento Therapeutics reported the acquisition of exclusive distribution rights from Samyang Biopharmaceuticals to Cynviloq (marketed as Genexol-PM in South Korea) in the 27 countries of European Union (EU) (Press release Sorrento Therapeutics, MAY 13, 2013, View Source [SID:1234500326]). IGDRASOL had previously obtained the exclusive U.S. distribution rights to Cynviloq from Samyang. STI has the right to acquire IGDRASOL pursuant to a previously-announced option agreement, entered into in March 2013.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!